Providence First Trust’s Biogen BIIB Stock Holding History

Providence First Trust’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$902K	Buy	4,175 +1,096	+36%	+$210K	0.25%	107
2026 Q1	$564K	Buy	+3,079	New	+$567K	0.2%	111

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Providence First Trust's BIIB Position: Q2 2026 in Review

Providence First Trust increased its Biogen (BIIB) stake by 36% in Q2 2026, buying an estimated $210K and bringing the position to 4,175 shares worth $902K. The position accounts for 0.25% of the portfolio, ranked #107.

Providence First Trust first reported a position in BIIB in Q1 2026 and has held it in 2 quarters since. 1,045 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Providence First Trust held 4,175 shares of Biogen worth $902K as of Q2 2026.
Providence First Trust bought 1,096 Biogen shares in Q2 2026, an estimated $210K.
Biogen made up 0.25% of Providence First Trust's portfolio in Q2 2026, its #107 holding.
Providence First Trust first reported a position in Biogen in Q1 2026 and has held it in 2 quarters since.
1,045 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Providence First Trust's 13F filing for Q2 2026, filed 27 Jul 2026.